论文部分内容阅读
在新近诊断为炎症性肠病(IBD)的患者中,大约有9%~12%的患者年龄超过60岁。大量观察研究表明,老年初发IBD患者和年轻初发IBD患者临床表现不尽相同,故其治疗方案也存在差异。糖皮质激素是老年初发IBD患者最常用的抗炎治疗药物,但糖皮质激素的使用和高龄均是诱发感染的独立危险因素,而感染可增加住院老年IBD患者的病死率。加拿大魁北克省犹太总医院的Brassard等对老年发病IBD患者使用口服糖皮质激素与产生严重感染相关的风险进行了研究。
In newly diagnosed patients with inflammatory bowel disease (IBD), approximately 9% to 12% of patients are over 60 years of age. A large number of observational studies have shown that the clinical manifestations of IBD patients and elderly patients with early onset IBD are not the same, so the treatment options are also different. Glucocorticoids are the most commonly used anti-inflammatory drugs in elderly patients with newly diagnosed IBD. However, the use of glucocorticoids and elderly patients are both independent risk factors for infection. However, infection can increase the mortality of hospitalized elderly IBD patients. Brassard et al., Jewish General Hospital, Quebec, Canada, studied the use of oral glucocorticoids and the risk of developing serious infections in elderly patients with IBD.